FUNDAMENTALS · Fundamentals · US Healthcare

Eton Pharmaceuticals (ETON) Fundamentals 2026 — Revenue Analysis | SniperIQ

Eton Pharmaceuticals (ETON) is a US-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of

.2B, trading at $43.47 on the NASDAQ. This SniperIQ fundamentals page covers Eton Pharmaceuticals's valuation, profitability (net margin -1.7%), revenue ($80M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap
.2B
Net Margin-1.7%
Revenue (FY25)$80M

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Eton Pharmaceuticals's market cap?

Eton Pharmaceuticals (ETON) has a market capitalization of approximately

.2B, trading at $43.47 on the NASDAQ. Market cap moves with the live share price.

What is Eton Pharmaceuticals's P/E ratio?

Eton Pharmaceuticals's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 38.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Eton Pharmaceuticals?

Eton Pharmaceuticals runs a net profit margin of -1.7%, a gross margin of 54.8%, and an operating margin of 2.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Eton Pharmaceuticals generate?

Eton Pharmaceuticals reported revenue of $80M for fiscal year 2025, with net income of -$5M and earnings per share (EPS) of -0.17. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Eton Pharmaceuticals pay a dividend?

Eton Pharmaceuticals does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Eton Pharmaceuticals financially healthy?

Eton Pharmaceuticals carries a debt-to-equity ratio of 0.40x and a current ratio of 1.21x, with a market beta of 0.86. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Eton Pharmaceuticals a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Eton Pharmaceuticals (ETON) the key facts are: market cap

.2B, revenue $80M, 52-week range 13.78-43.9328. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Eton Pharmaceuticals's full fundamentals live

Get Eton Pharmaceuticals's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Duopharma Biotech (7148) fundamentals · Alpha Tau Medical (DRTS) fundamentals · MannKind (MNKD) fundamentals · Avanos Medical (AVNS) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons